Gsa Capital Partners LLP Coherus Bio Sciences, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	SELL	$1.59 - $3.85 $115,597 - $279,906	-72,703 Reduced 75.22%	23,950 $79,000
Q3 2023 Nov 15, 2023	SELL	$3.74 - $5.45 $92,475 - $134,756	-24,726 Reduced 20.37%	96,653 $361,000
Q2 2023 Aug 14, 2023	BUY	$3.79 - $8.3 $211,110 - $462,326	55,702 Added 84.81%	121,379 $518,000
Q1 2023 May 12, 2023	SELL	$5.89 - $10.52 $66,922 - $119,528	-11,362 Reduced 14.75%	65,677 $449,000
Q4 2022 Feb 13, 2023	BUY	$5.69 - $10.07 $438,351 - $775,782	77,039 New	77,039 $610,000
Q1 2022 May 11, 2022	SELL	$10.92 - $16.41 $194,168 - $291,786	-17,781 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $281,117 - $337,661	17,781 New	17,781 $284,000
Q3 2021 Nov 12, 2021	SELL	$12.68 - $17.79 $157,904 - $221,538	-12,453 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$12.95 - $15.41 $161,266 - $191,900	12,453 New	12,453 $172,000
Q1 2020 May 12, 2020	SELL	$11.67 - $22.53 $501,028 - $967,280	-42,933 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$16.33 - $21.37 $475,562 - $622,337	29,122 Added 210.86%	42,933 $773,000
Q3 2019 Nov 12, 2019	BUY	$16.3 - $23.37 $225,119 - $322,763	13,811 New	13,811 $280,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.